Jakavi or Jakafi (generic name: ruxolitinib) is a prescription drug manufactured by Novartis approved for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis , post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar tissue.
It comes in tablet form & pack size of 56 tablets ( 4 strips of 14 tablets). Available in dosage of is 5 mg, 15 mg & 20 mg.
Note: Also known as Jakafi in other parts of the world
Manufacturer: Novartis